Grifols (GRFS) Expected to Announce Quarterly Earnings on Wednesday

Grifols (NASDAQ:GRFS) is projected to announce its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $1.86 billion for the quarter.

Grifols Trading Up 0.8 %

Shares of NASDAQ:GRFS opened at $7.38 on Wednesday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols has a twelve month low of $5.30 and a twelve month high of $9.96. The firm has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $8.09.

Wall Street Analysts Forecast Growth

GRFS has been the subject of several recent analyst reports. Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th. Morgan Stanley initiated coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.